Estabrook Capital Management cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 24.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,600 shares of the medical instruments supplier’s stock after selling 860 shares during the quarter. Estabrook Capital Management’s holdings in Becton, Dickinson and were worth $509,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Westwood Holdings Group Inc. lifted its stake in Becton, Dickinson and by 24.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after acquiring an additional 205,721 shares in the last quarter. Colony Group LLC lifted its stake in Becton, Dickinson and by 2.1% in the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after acquiring an additional 239 shares in the last quarter. State Street Corp lifted its stake in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp lifted its stake in Becton, Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after acquiring an additional 453 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after acquiring an additional 11,300 shares in the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

In other news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $226.28 on Monday. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $227.50. The stock has a market capitalization of $51,586.86, a P/E ratio of 23.84, a PEG ratio of 1.77 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the prior year, the business posted $2.12 EPS. The business’s revenue was down 2.0% compared to the same quarter last year. research analysts forecast that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.75 per share. The ex-dividend date is Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.33%. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio is currently 62.80%.

Several research firms have commented on BDX. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 target price on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Tuesday, October 31st. Cowen Inc restated a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Barclays PLC restated an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $217.08.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-estabrook-capital-management/1728798.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.